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Abstract 
Introduction: The efficacy of misoprostol use 
for cervical priming before intrauterine device 
insertion (IUD) is controversial. This review aims 
to evaluate the evidence from published 
randomized controlled trials about the efficacy 
and safety of misoprostol before IUD insertion 
for pain relief in women with no previous vaginal 
delivery.  
Materials and methods: We searched the 
following electronic databases: Web of Science, 
Cochrane CENTRAL, SCOPUS, and PubMed 
for relevant studies using the following Mesh 
terms: (misoprostol) AND (intrauterine device 
OR IUD). The primary outcome was the mean 
pain score during insertion. Secondary 
outcomes included the ease of insertion score, 
the rate of successful IUD insertion, the rate of 
IUD insertion failure, and the adverse effects. 
Results: Ten randomized controlled trials 
(RCTs) (misoprostol: n=698 and placebo: 
n=689) were pooled in the analysis. The overall 
Standardized Mean Difference (SMD) of pain 
score did not favor either of the two groups 
(SMD= -0.09, 95%CI [-0.50, 0.33], p=0.007). 
Pooled results were highly heterogeneous 
(I2=93%, P<0.001). The total MD of the ease of 
insertion score favored the misoprostol group 
(MD= -1.36, 95% CI [-2.20, -0.52], p =0.002). 
The overall risk ratio (RR) of the number of 
failed insertions showed that misoprostol is 
associated with less IUD insertion failures 
compared to placebo (RR=0.55, 95% CI [0.38, 
0.81], p=0.002). Finally, the overall risk showed 
that misoprostol is associated with more 
shivering, diarrhea and pelvic pain. 
Conclusions: Misoprostol facilitates IUD 
insertion in women with no previous vaginal 
delivery, and is associated with 50% less 
chance for IUD insertion failure despite inducing 
mild adverse effects 
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Introduction 
The intrauterine device (IUD) is one of 
the best contraceptive methods 
currently used worldwide. The World 
Health Organization (WHO) estimates 
that the IUD is used by over 160 million 
women (15.5%) of childbearing age 
worldwide.1 It is a cheap, reversible, 
long-acting and highly effective method 
of contraception.2 
Nulliparous women and those who have 
never delivered vaginally before are 
suspected of having more difficulty and 
pain during IUD insertion.3 Such 
difficulty could be attributed to the tight 
cervical os in those women.4Several 
researchers have studied the impact of 
various medications to facilitate and 
relieve pain during IUD insertion such as 
lidocaine, misoprostol, and 
nitroprusside.5 
Misoprostol is a synthetic prostaglandin 
E1 (PGE1) analog.6 It can be 
administrated vaginally, rectally, orally, 
buccally and sublingually.7 Its low price, 
easy administration, and easy storage 
make it more popular than other forms 
of PGs. It is widely used in obstetrics 
and gynecology mainly to induce 
cervical ripening and dilatation.6 
Therefore, it is mainly used for early 
termination of pregnancy and induction 
of labor.8 It is also used to prevent 
postpartum hemorrhage.9,10 
Due to the effect of misoprostol on the 
cervix, there is a growing hypothesis 
that misoprostol can reduce the pain 
perception in women during IUD 
insertion and increase the ease of 
insertion. Several studies have 
evaluated this hypothesis with 
contradictory results regarding the pain 
perception and ease of IUD insertion.11-
13  
Therefore, in this review; we aim to 
systematically evaluate the available 
evidence from randomized controlled 
trials (RCTs) regarding the efficacy and 
safety of misoprostol before IUD 
insertion for pain relief in women with no 
previous vaginal delivery. 
Materials and Methods  
We carried out this systematic review 
according to the Preferred Reporting 
Items for Systematic Reviews and Meta-
analyses (PRISMA) guidelines14 and 
was registered in PROSPERO 
(CRD42018109811). Because this study 
was a systematic review and meta-
analysis, formal ethical approval was not 
required. 
Search strategy 
Three authors conducted an electronic 
search using several databases 
including Web of Science, Cochrane 
CENTRAL, SCOPUS, and PubMed for 
relevant studies from inception to 
October 2019. Combinations of the 
following MeSH terms were used: 
(misoprostol) AND (intrauterine device 
OR IUD OR intrauterine system OR IUS 
OR intrauterine contraception). We 
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examined the reference lists of all 
retrieved primary and review articles to 
identify cited articles not captured by 
electronic searches. 
Eligibility criteria 
We considered all published studies that 
satisfied the following criteria:  
1. Population: women requesting 
IUD insertion who had never 
delivered vaginally, either 
nulliparous or delivered only by 
elective cesarean section. 
2. Intervention: misoprostol 
administration before insertion 
3. Comparator: placebo 
4. Outcomes: the primary outcome 
was the pain score during 
insertion. Secondary outcomes 
included the ease of insertion 
score, number of failed 
insertions, number of successful 
insertions, and rate of adverse 
effects related to misoprostol use 
(abdominal discomfort, vaginal 
bleeding, diarrhea, and 
shivering). 
5. Study design: randomized clinical 
trials (RCTs). 
We excluded studies for the following 
reasons: 
1. Non-randomized trials 
2. In vitro and animal studies  
3. Non-English studies 
4. Studies whose data were 
unreliable for extraction and 
analysis 
5. Studies on misoprostol use after 
previous insertion failure. 
Duplicates were removed,and retrieved 
references were screened in two steps: 
the first step was to screen titles and 
abstracts for matching our inclusion 
criteria and the second step was to 
screen the full-text articles of eligible 
abstracts for eligibility to meta-analysis. 
Study selection 
The title and abstract of all identified 
articles were screened independently by 
three reviewers to assess relevance to 
this meta-analysis. In case of 
disagreement, the full text of such 
studies was retrieved and reviewed 
independently by a senior author (AMA) 
for a final decision. 
All identified articles were evaluated 
according to a standardized format 
including study design, methods, 
participant characteristics, intervention, 
and results. Two reviewers scored the 
studies and collected the information 
independently. In case of discrepancies 
in scoring, a consensus was reached 
after consultation of the study mentor 
(AS). 
Data extraction and analysis 
From each study, we extracted the 
study characteristics such as 
participants’ baseline characteristics, 
study outcomes, and adverse effects of 
the drug or the placebo. Additionally, 
details for risk of bias were extracted, 
such asthe method of randomization, 
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allocation concealment, blinding, 
intention-to-treat analysis, and follow-up 
rates. One study (Dijkhuizen et al.15) 
reported both nulliparous and 
multiparous (delivering vaginally) 
women, only data of nulliparous women 
were extracted. 
All data were entered into RevMan 
software (Review Manager, version 5.1, 
The Cochrane Collaboration, 2011; The 
Nordic Cochrane Centre, Copenhagen, 
Denmark) for meta-analysis. The mean 
difference (MD)and 95% confidence 
interval (CI) were calculated for 
continuous data, while the relative risk 
(RR) and 95% CI were calculated for 
dichotomous data. 
Statistical heterogeneity between 
studies was evaluated graphically using 
forest plots and statistically using I-
squared (I2) test. Values of ≥50% were 
indicative of high heterogeneity. When 
heterogeneity was significant, a random-
effects model was used for meta-
analysis. Fixed effect meta-analysis was 
used when there was no significant 
heterogeneity. Pooled analyses of data 
from all studies were performed for 
various outcomes.  
Risk of bias assessment 
We assessed the risk of bias according 
to the Cochrane risk of bias tool, which 
is described in the Cochrane Handbook 
for Systematic Reviews of Interventions 
5.1.0.16 We used the quality assessment 
table provided (part 2, Chapter 8.5). 
Assessment included the following 
domains: random sequence generation 
(selection bias), allocation sequence 
concealment (selection bias), blinding of 
participants and personnel (performance 
bias), blinding of outcome assessment 
(detection bias), incomplete outcome 
data (attrition bias), selective outcome 
reporting (reporting bias) and other 
potential sources of bias. The authors’ 
judgment is categorized as low, unclear 
or high risk of bias. 
Publication bias 
Although the number of included studies 
in the current analysis was ten studies, 
we could not assess the publication bias 
using the Egger test as each outcome 
includes less than ten studies.  
Results 
Characteristics of included studies 
Our search retrieved 231 unique 
citations from searching electronic 
databases. We excluded 191 studies 
that did not meet our inclusion criteria 
and removed the duplicates using 
Endnote software. After reading the full 
text of forty studies, we excluded thirty 
studies which were ineligible. We 
searched the references of the included 
RCTs manually, but we did not find any 
more relevant records. Ten RCTs 
recruited 1387 women (misoprostol: 
n=698 and placebo: n=689) who 
underwent IUD insertion were finally 
included in this meta-analysis (Figure 1). 
The characteristics of the included 
studies are summarized in 
Supplemental Table. 
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Figure 1: PRISMA Flow Chart of the study selection process, using RevMan 
software for windows. 
 
Potential source of bias  
According to the Cochrane risk of bias 
assessment tool, the risk of bias 
assessment was low. Ten studies 
specified their methods of randomization 
of patients, nine of them reported 
allocation concealment, and nine of 
them also reported proper blinding of 
participants and personnel. Two studies, 
Saav et al.7 and Ibrahim et al.,17 
reported no blinding of participants; 
therefore, they were categorized as high 
risk. Eight studies reported proper 
blinding of outcome assessment, and 
six studies had a low risk of reporting 
bias. No other bias was found and no 
missing data as well. The quality of the 
included studies ranged from moderate 
to high quality. A summary of quality 
assessment domains is shown in Figure 
2. 
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Figure 2: Diagram of quality assessment of included studies (A) and Risk of bias 
summary graph (B) according to Cochrane’s risk of bias assessment tool. 
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Outcomes 
Pain Score during insertion 
 
The overall Standardized Mean 
Difference of pain score did not favor 
either of the two groups (SMD= -0.09, 
95%CI [-0.50, 0.33], p=0.007). Pooled 
results were highly heterogeneous 
(I2=93%, P<0.001) due to the diversity of 
drug doses (200, 400, and 600 mcg) 
and different routes of administration 
(oral, vaginal, and sublingual). 
Therefore, subgroup analysis was 
performed to investigate the effect of 
different doses and routes of 
administration on pain outcome.  
First: According to the route of 
administration, we found that 
misoprostol was not effective whether 
given orally, vaginally, or sublingually.  
1. Oral route: the SMD did not favor 
either of the two groups (SMD= 
0.24, 95%CI [-0.16, 0.63], 
p=0.24). Pooled results were 
heterogeneous (I2=61%, P=0.05). 
(Figure 3a). Heterogeneity was 
best resolved by excluding Espey 
et al.12 Results favored the 
placebo over misoprostol after 
exclusion (SMD= 0.43, 95% CI 
[0.14, 0.72], p=0.003, I2=0%, 
P=0.9) (Figure 3b) 
 
 
Figure 3a: Forest plot for subgroup analysis of the Pain Score outcome by route, 
before leave-one-out analysis 
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2. Vaginal route: the SMD did not 
favor either of the two groups 
(SMD= -0.67, 95%CI [-1.71, 
0.38], p=0.21). Pooled results 
were highly heterogeneous 
(I2=96%, P<0.001; Figure 3a). 
Heterogeneity could not be 
solved by the leave-one-out 
method. 
3. Sublingual route: the SMD did not 
favor either of the two groups 
(SMD= 0.23, 95%CI [-0.07, 0.54], 
p=0.14). Pooled results were 
heterogeneous (I2=73%, P=0.03; 
Figure 3a). Heterogeneity was 
best resolved by excluding 
Mansi, 2018 study.18 Results 
favored the placebo over 
misoprostol after exclusion 
(SMD= 0.39, 95% CI [0.18, 0.61], 
p=0.0004, I2=0%, P=0.9; Figure 
3b) 
 
Figure 3b: Forest plot for subgroup analysis of the Pain Score outcome by route, 
after leave-one-out analysis 
Second: depending on the misoprostol 
dose, we found that misoprostol reduces 
IUD insertion pain when given at a high 
dose (600mcg) and is not effective when 
given at low doses (200 & 400mcg). 
Nine studies used a dose of 400mcg 
misoprostol, the analysis of the nine 
studies did not favor either of the two 
groups (SMD= 0.02, 95% CI [-0.58, 
0.53], p=0.9). Pooled results were 
heterogeneous (I2=94%, p<0.0001; 
Figure 4a). 
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Figure 4a: Forest plot for subgroup analysis of the Pain Score outcome by dose, 
before leave-one-out analysis. 
Heterogeneity was best resolved by 
excluding the Abdellah et al. study.13 
Results favored the placebo arm over 
misoprostol (SMD= 0.25, 95%CI [0.07, 
0.43], p=0.006, I2=34%, P=0.15; Figure 
4b). 
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Figure 4b: Forest plot for subgroup analysis of the Pain Score outcome by dose, 
after leave-one-out analysis 
 
Only one study, Mansi, 2018,18 reported 
the use of 200 mcg dose and found no 
significant difference between groups 
(MD= -0.01, 95% CI [-0.20, 0.19], 
p=0.9). Similarly, only one study Maged 
et al.19 reported the use of 600mcg dose 
and found a significant difference 
favoring the drug over the placebo 
group (MD= -0.68, 95% CI [-1.04, -0.31], 
p=0.003). 
Ease of insertion score 
 
The pooled mean difference (MD) of the 
ease of insertion score favored the 
misoprostol group over the placebo 
group (MD= -1.22, 95% CI [-1.72, -0.73], 
p<0.0001). Pooled results were 
homogeneous (P =0.15, I2 = 48%; 
Figure 5). 
Number of successful insertions 
 
The pooled risk ratio did not favor either 
of the two groups (RR= 1.04, 95% CI 
[1.00, 1.08], p=0.06). However, the data 
were heterogeneous (p=0.06, I2= 50%; 
Figure 6a). Heterogeneity was best 
resolved by excluding Lathrop et al.20 
Pooled results favored the misoprostol 
group (RR= 1.05, 95% CI [1.01, 1.08], 
p=0.01; Figure 6b) 
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Figure 6a: Forest plot for successful IUD insertions outcome, before leave-one-
out analysis. 
 
Figure 6b: Forest plot for successful IUD insertions outcome, after leave-one-out 
analysis. 
 
Number of Failed Insertions 
 
The overall risk ratio of failed insertions 
showed that misoprostol is associated 
with less IUD insertion failures 
compared to placebo (RR= 0.55, 95% 
CI [0.38, 0.81], p=0.002). Pooled results 
were homogenous (p=0.47, I2 = 0%; 
Figure 7). 
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Figure 7: Forest plot for failed IUD insertions outcome. 
 
Misoprostol adverse effects 
 
1. Shivering: the overall risk showed 
that misoprostol is associated 
with more shivering (RR =5.22, 
95% CI [2.16, 12.59], p= 0.0002). 
Pooled results were homogenous 
(p =0.77, I2 =0%) (Figure 8a). 
2. Diarrhea:the overall risk ratio 
showed that misoprostol is 
associated with more diarrhoea 
(RR =2.64 95% CI [1.24, 5.66], 
p= 0.01). Pooled results were 
homogenous (p =0.59, I2 =0%) 
(Figure 8b). 
3. Abdominal or pelvic pain: the 
overall risk ratio showed that 
patients in misoprostol group had 
more incidence of pelvic pain 
(RR= 8.00, 95% CI [4.07, 15.74]). 
Pooled results were homogenous 
(p= 0.13, I2= 48%) (Figure 8c). 
4. Vaginal bleeding during insertion: 
no significant difference was 
found between both groups 
regarding vaginal bleeding (RR 
=1.35, 95% CI [0.77, 2.38], p= 
0.29). Pooled results were 
homogenous (p =0.13, I2 =47%) 
(Figure 8d). 
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Figure 8: Forest plot for misoprostol adverse effects, A) shivering, B) Diarrhea, C) 
Abdominal pain, and D) Vaginal bleeding during insertion. As shown in the 
figures, misoprostol significantly causes slight adverse effects than placebo 
(except in vaginal bleeding) 
Discussion 
The present systematic review showed 
that the administration of misoprostol 
before IUD insertion significantly 
facilitates the process of insertion and is 
associated with less IUD insertion 
failures in women with no previous 
vaginal delivery. However, it does not 
decrease the associated pain with the 
Proceedings in Obstetrics and Gynecology, 2020;10(1):2 
Misoprostol and IUD insertion 14 
 
procedure. 
The role of misoprostol in cervical 
priming in non-pregnant women before 
office gynecological procedures is not 
well established despite many previous 
publications in the literature. However, 
there are reports of its effectiveness in 
inducing cervical dilation and hence 
decreasing the incidence of procedural 
resistance and associated non-
compliance.21,22 Zhou et al. in their 
systematic review stated that 
misoprostol had a significant effect on 
cervical ripening before hysteroscopy.23 
Similarly, Hou et al. found that 
misoprostol is effective for cervical 
ripening and increasing the ease of IUD 
removal with less pain perception in 
postmenopausal women.24 On the other 
hand, Zapata et al. and Matthews et al. 
in two systematic reviews evaluated the 
use of misoprostol before IUD insertion 
among patients of any parity found no 
evidence to support routine 
administration of misoprostol before IUD 
insertion.25,26 There were no differences 
in success of insertion, difficulty of 
insertion and pain perception with prior 
administration of misoprostol. 
In the present review, three studies 
measured the ease of insertion score by 
a VAS scale and reported their results. 
Two of them showed that misoprostol 
facilitates IUD insertion significantly, 
while only one reported no difference. 
The net analysis favored the misoprostol 
group. 
Regarding the pain associated with the 
procedure, many studies used different 
doses and routes of administration to 
investigate the effect of the drug on pain 
perception. We performed two subgroup 
analyses separately in an attempt to 
accurately describe the effect of the 
drug on pain and the role of different 
doses and routes of administration. 
The analysis showed that misoprostol is 
not effective whether given orally, 
vaginally, or sublingually. Low doses 
(200 & 400 mcg) did not demonstrate 
any effect; however, high dose (600 
mcg) was associated with a significant 
decrease in pain score. 
Due to this variety of doses and routes 
of administration, we encountered high 
heterogeneity among our included 
studies, which may have masked and 
influenced the effect of the drug on 
different outcomes. 
After using the leave-one-out method 
provided by Cochrane’s handbook, we 
found that the misoprostol group had 
significantly higher pain scores than 
placebo when administered orally and 
sublingually, and similar pain scores 
when administered vaginally. 
It is reported that pain tolerability is less 
in nulliparous,22 and women who 
delivered only by cesarean section (CS) 
compared to women who delivered 
vaginally.13 This may affect the 
outcomes of certain studies such as 
Edelman et al.,27 Espey et al.,12 Lathrop 
et al.,20 Saav et al.7and Swenson et al.28 
Some researchers reported that delivery 
by CS only might be associated with 
failure of IUD insertion, which can be 
explained by the presence of scar at the 
internal OS interfering with cervical 
ripening.29 This could explain the high 
failure rate reported by Mansy.18 
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Our findings are supported by the fact 
that misoprostol has long been used to 
reduce pain in various gynecological 
procedures. Although many 
interventions had been compared to it, 
the results favored misoprostol. Esin et 
al. reported that misoprostol is more 
effective than lidocaine in reducing pain 
associated with hysteroscopy.30 Issat et 
al. reported the same results, and 
additionally, it was found that the effect 
of misoprostol is not affected by 
patients’ age, hormonal status, parity, or 
type of hysteroscopy.31Fouda et al. 
found that misoprostol is more effective 
than uterine straightening by bladder 
distension and that the insertion of the 
hysteroscope was easier in the 
misoprostol group.32 
According to a review by Grimes et al. 
non-steroidal anti-inflammatory drugs 
(NSAIDs) have shown a great effect in 
reducing pain during IUD insertion.33 
There was a debate among previous 
studies comparing misoprostol to 
NSAIDs. During endometrial biopsies, 
Telli et al. did not find a significant 
difference between misoprostol and 
NSAIDs regarding pain relief.34 Hassa et 
al. found that in hysterosalpingography 
(HSG), NSAIDs did not differ 
significantly compared to misoprostol 
regarding pain relief 30-min after the 
procedure. However, NSAIDs have a 
favorable outcome in relieving pain 
during the procedure.35 
The known reported adverse effects of 
misoprostol include diarrhea, abdominal 
pain, shivering, and vaginal bleeding 
during IUD insertion. The distribution of 
adverse effects showed increased side 
effects in the misoprostol group 
compared to the control group (except 
vaginal bleeding, which did not 
differ).The adverse effects are affected 
by the dose and route of 
administration.36 The included studies in 
our meta-analysis reported different 
routes of administration including 
(buccal, sublingual and vaginal). Vaginal 
and buccal misoprostol isassociated 
witha slow rate of absorption and 
clearance with a lower peak plasma 
level.37,38 
Unlike both of them is the sublingual 
route of administration which has a rapid 
rate of absorption and higher peak 
plasma level,38 hence associated with a 
higher rate of GIT side 
effects.Thisexplains the elevated rates 
of gastrointestinal side effects in Saavet 
et al.,7 Mansy18 and Ibrahimet et al.17 
studies in which they used the 
sublingual route for administration of 
misoprostol. The rate of abdominal and 
pelvic pain showed a consistent 
increase in the misoprostol group 
compared to the control group across 
the studies regardless ofthe route of 
administration. No evidence of a 
significant difference between the two 
groups in the incidence of bleeding. 
However, shivering was significantly 
more prevalent in the misoprostol group. 
Regarding the number of failed 
insertions in each group, we found that 
the number of failed insertions in the 
misoprostol group is half that of the 
control (0.1% of the population in the 
control group had failed insertions 
compared to 0.05% in the misoprostol). 
As for the number of successful 
insertions, the analysis did not favor 
either of the two groups; however, this 
may be due to high heterogeneity 
among the studies. The analysis, when 
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done on a fixed-effects model favors 
misoprostol significantly (p =0.002). 
Additionally, the results of failed 
insertion showed less failure in the 
misoprostol group. Therefore, the effect 
of misoprostol on successful insertions 
is clinically significant. The presence of 
heterogeneity among studies may have 
masked it. 
Further trials reporting the ease of 
insertion score and pain scores with 
different doses are recommended. 
Additionally, more RCTs need to be 
done comparing misoprostol to NSAIDs.  
Strengths 
Our meta-analysis includes ten RCTs, 
which is a good number for providing a 
‘clinically significant’ evidence for our 
findings. We excluded any studies other 
than RCTs, and to our knowledge, this 
is the first systematic review and meta-
analysis that evaluated the efficacy and 
safety of misoprostol administration in 
women with no previous vaginal 
delivery. 
Limitations 
There are some limitations to our study: 
firstly, the use of different routes of 
administration of misoprostol across the 
studies (buccal, sublingual and vaginal) 
which affect the rate of absorption, peak 
plasma level and rate of clearance 
hence the efficacy and side effects of 
the drug.34Moreover, the administration 
of different doses and by different routes 
of administration resulted in significant 
heterogeneity among the studies. This 
heterogeneity may have masked and/or 
influenced the effect of misoprostol on 
our outcomes. Considering the high 
heterogeneity, one wonders if pooling of 
these studies is appropriate.The pooled 
sample size also may not be adequately 
powered to detect meaningful 
differences, as the insertion success 
rate was overall very high. Finally, the 
ease of insertion score outcome was 
reported in only three of ten studies. 
Conclusion  
Misoprostol significantly facilitates the 
process of IUD insertion and is 
associated with half the insertion failure 
rate compared to the control groups in 
women with no previous vaginal 
delivery. However, it does not decrease 
pain perception associated with IUD 
insertion. 
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